Clinical Trials

Beginning in May of 2006, in a first-of-its-kind individualized treatment trial called TAILORx (Trial Assigning IndividuaLized Options for Treatment (Rx), the National Cancer Institute (NCI)) part of the National Institutes of Health, initiated a landmark trial which used Oncotype DX to identify and assign treatment to more than 10,000 breast cancer patients from 1,500 sites in the United States, Canada, Ireland and Peru. Coordinated by the Eastern Cooperative Oncology Group (ECOG), TAILORx was designed to evaluate the effect of chemotherapy in women with a midrange risk of their cancer returning, as determined by the Oncotype DX breast cancer assay. The trial will evaluate the effect of chemotherapy only for those with a midrange Recurrence Score^®, as previous Oncotype DX studies have already confirmed the benefit of adjuvant chemotherapy for those in the high Recurrence Score range and minimal, if any, benefit for those in the low Recurrence Score range. The TAILORx trial is ongoing, but not recruiting patients. For further information regarding TAILORx and closure of the trial, please visit the ECOG website.